FreeCME

Emerging Immunotherapies for Hematologic Malignancies: Improving Patient Outcomes by Harnessing the Immune System

Jointly provided by The Leukemia & Lymphoma Society, Postgraduate Institute for Medicine and RMEI, LLC.

Funding provided by The Leukemia & Lymphoma Society.

Scroll to the Bottom of this Information to Begin this Course

Release date: March 12, 2015

Valid through: March 12, 2016

Specialty: Hematology, Oncology

Estimated Time to Complete Activity: 3 hours and 30 minutes for all 5 modules

Media: Internet

Target Audience

This activity is primarily for researchers in hematology/oncology, and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies; it is also intended for others with an interest in hematologic malignancies. This program is designed to provide the intended audience with the most current and accurate information about therapeutic advances in immunology for treating and improving outcomes for patients with hematologic malignancies.

Learning Objectives

PD-1 and the Landscape Beyond: Checkpoint Blockade in Hematologic Cancer – Module 1

Alexander M. Lesokhin, MD

Upon completion of this activity, participants should be better able to:

  1. Describe advances in the current understanding of immunology as they pertain to the treatment of hematologic malignancies
  2. Explain the current status and therapeutic potential of immuno-therapies, in particular immune checkpoint inhibitors, for several hematologic malignancies
  3. Describe key factors related to moving immunotherapies such as immune checkpoint inhibitors forward in a timely fashion

Start Module 1

Small Molecule Immunomodulatory Drugs - Module 2

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Upon completion of this activity, participants should be better able to:

  1. Explain the mechanisms whereby hematologic cancer cells alter host immune responses
  2. Describe how changes in host immune response to hematologic cancer cells can be prevented or reversed by immunomodulatory drugs including lenolidomide
  3. Discuss host immune responses as targets of novel therapeutic approaches to treat hematologic malignancies

Start Module 2

Priming Autologous T Cells Against EBV - Module 3

Helen E. Heslop, MD, DSc (Hon)

Upon completion of this activity, participants should be better able to:

  1. Describe the types of Epstein Barr Virus (EBV) latency and associated hematologic malignancies
  2. Discuss the role of T cell therapy for EBV lymphomas
  3. Outline advantages and disadvantages of “off-the-shelf” T cell therapies

Start Module 3

CAR T Cells Therapy: The CD19 Paradigm - Module 4

Michel Sadelain, MD, PhD

Upon completion of this activity, participants should be better able to:

  1. Describe the goals of T cell immunotherapy for hematologic malignancies
  2. Discuss current technological advances with CD 19-targeted chimeric antigen receptor (CAR) T cell therapy
  3. Outline challenges in CD 19 CAR T cell therapy

Start Module 4

Panel Discussion and Q&A: How Do We Operationalize and Move Immunologic Strategies Forward In A Timely Fashion? – Module 5

Owen A. O’Connor, MD, PhD, Alexander M. Lesokhin, MD, John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Helen E. Heslop, MD, DSc, (Hon), Michel Sadelain, MD, PhD

Upon completion of this activity, participants should be better able to:

  1. Discuss the current technological advances, as well as the evolving knowledge about tumor targets, contributing to clinical advances using antibody drug conjugates to treat hematologic malignancies
  2. Describe key factors related to moving immunotherapies forward in a timely fashion
  3. Demonstrate the ability to identify patients with hematologic malignancies who are appropriate candidates for an immuno-oncology treatment approach and engage them in discussions regarding clinical trials

Start Module 5

Credit Available

  • Physicians — maximum of 3.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Faculty

Owen A. O’Connor, MD, PhD
Professor of Medicine and Experimental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY

Alexander M. Lesokhin, MD
Assistant Attending Physician, Myeloma Service and
Immunotherapeutics Core
Memorial Sloan-Kettering Cancer Center
New York, NY

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Barts and the London School of Medicine and Dentistry
Queen Mary University of London
London, UK

Helen E. Heslop, MD, DSc (Hon)
Dan L. Duncan Chair
Interim Director, Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Stephen and Barbara Friedman Chair
Member, Immunology Program
Departments of Medicine and Pediatrics
Memorial Sloan-Kettering Cancer Center
New York, NY

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Leukemia & Lymphoma Society, Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Module 1

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Start Module 1

Module 2

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Start Module 2

Module 3

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Start Module 3

Module 4

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Start Module 4

Module 5

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Start Module 5

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Owen A. O’Connor, MD, PhD
  • Consulting fees: Celgene, Seattle Genetics, Mundipharma, and Millennium
Alexander M. Lesokhin, MD
  • Property Rights/Patent Holder: Serametrix/MDSC Assay
  • Consulting fees: Bristol-Myers Squibb, Foundation Medicine
  • Contracted Research: Bristol-Myers Squibb
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
  • Consulting fees: Roche/Genentech, Pharmacyclics, Mundipharma, AbbVie, Celgene, and MorphoSys
Helen E. Heslop, MD, DSc (Hon)
  • Royalty and Contracted Research: Celgene
Michel Sadelain, MD, PhD
  • Advisory Board and Ownership Interest: Juno Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Leukemia & Lymphoma Society planners and managers, Lee Greenberger, PhD, Yixian Zhang, PhD, Nikay Thomas, and Clare Karten, MS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following RMEI, LLC planners and managers, Nora Hartley, MLIS and Lillian McVey, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must read the learning objectives and faculty disclosures; study the educational activity; and complete the post-test and the evaluation form. If you pass the post-test and complete the evaluation, your certificate will be available immediately for download in PDF format.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Start Module 1 - PD-1 and the Landscape Beyond: Checkpoint Blockade in Hematologic Cancer

Start Module 2 - Small Molecule Immunomodulatory Drugs

Start Module 3 - Priming Autologous T Cells Against EBV

Start Module 4 - CAR T Cells Therapy: The CD19 Paradigm

Start Module 5 - Panel Discussion and Q&A: How Do We Operationalize and Move Immunologic Strategies Forward In A Timely Fashion?